Feb 26, 2021 / 04:20PM GMT
Joseph Patrick Schwartz - SVB Leerink LLC, Research Division - MD of Rare Diseases & Senior Research Analyst
Hello. Welcome to this fireside chat with BioMarin Pharmaceutical. I'm Joe Schwartz from the SVB Leerink Equity Research team. It's my pleasure to host management. Today, we're very pleased to have J.J. Bienaime, Chairman and CEO; Hank Fuchs, CMO; Brian Mueller, CFO. Welcome, gentlemen. Thanks for joining us.
Maybe we can start, J.J., by just having you give us a quick update on all of your activities and the news flow that investors should be on the lookout for this year.
Jean-Jacques Bienaime - BioMarin Pharmaceutical Inc. - Chairman & CEO
So as you know, we reported our Q4 yesterday, and I would say that the essential nature of our medicine resulted in strong growth despite, as you know, the global pandemic and the delay in ROCTAVIAN approval. As you're excluding Kuvan, BioMarin revenues grew 13% in 2020 and generated $85 million of positive operating cash flow. The '20 -- we gave guidance for '21. Our revenues are
Biomarin Pharmaceutical Inc at SVB Leerink Global Healthcare Conference (Virtual) Transcript
Feb 26, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers